Drugs / Enhancin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01267942 | May → Oct 2008 | adenoid hypertrophy | University of Nairobi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enhancin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01267942 ↗ |
| Known as | Co-Amoxiclav | “63 were given a single intravenous dose of Enhancin [Co-Amoxiclav] at induction while the remaining half received a five days oral course of the same postoperatively.” PMID 21961644 ↗ Sep 2011 |
| Route | Intravenous | “single intravenous dose of Enhancin [Co-Amoxiclav] at induction” PMID 21961644 ↗ Sep 2011 |
| Route | Oral | “single intravenous dose of Enhancin [Co-Amoxiclav] at induction” PMID 21961644 ↗ Sep 2011 |